NST-628 in Recurrent Grade 4 Glioma
About the Recurrent Grade 4 Glioma Clinical Trial
The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting an open-label Phase 0/1 clinical trial to evaluate NST-628 in patients with recurrent grade 4 glioma, with the primary objective of assessing central nervous system (CNS) penetration.
This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety and tolerability of NST-628 in participants, and will consist of a Phase 0 component and an Expansion Phase 1 component. NST-628 is a molecular glue. A molecular glue is a unique type of drug that interferes with specific protein interactions in a cell. As cancer therapies, they target pathways to prevent cancer cells from growing.
Glioma Trial Details
Recruiting
NST-628
Recurrent Grade 4 Glioma
Pending
You may be eligible if:
- You are 18 years or older.
- Diagnosed with Grade 4 glioma, who have progressed on or following standard of care therapy.
- Has sufficient archival or biopsy brain tumor tissue available to confirm eligibility.
- Is clinically indicated for tumor resection.
How it works
Once enrolled, a patient receives a short exposure to the experimental therapy days before a planned operation to remove their tumor.
The exposure to the experimental therapy is enough that when we remove the tumor, our team of experts can answer an important question: Did the treatment penetrate the tumor?
If the drug penetrates the tumor at sufficient levels, the patient may move forward with receiving the experimental treatment in the therapeutic expansion phase.
Alternatively, if the treatment has no effect on the tumor, the patient can enroll in another clinical trial without losing time or receiving ineffective treatment.
Am I Eligible?
Submit a free trial screening request today to learn if you may qualify for any of our studies.
